Tumor biomarkers, the substances which are produced by tumors or the body's responses to
tumors during tumorigenesis and progression, have been demonstrated to possess critical …

A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …

Pharmacological inhibition of the ataxia telangiectasia and Rad3-related protein
serine/threonine kinase (ATR; also known as FRAP-related protein (FRP1)) has emerged as …

Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising
anticancer strategy for tumors with DNA damage response (DDR) defects and replication …

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor
outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with …

The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …

AZD6738 (ceralasertib) is a potent and selective orally bioavailable inhibitor of ataxia
telangiectasia and Rad3-related (ATR) kinase. ATR is activated in response to stalled DNA …

Genome instability has been identified as one of the enabling hallmarks in cancer. DNA
damage response (DDR) network is responsible for maintenance of genome integrity in …

DDR (DNA damage response) defects in cells drive tumor formation by promoting DNA
mutations, which also provides cancer-specific vulnerabilities that can be targeted by …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have become a
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …